Atopic Dermatitis:
Atopic Dermatitis: Final Report
Multiple Myeloma:
Multiple Myeloma: Final Evidence Report and Meeting Summary
Carlson JJ, Guzauskas G, Chapman R, et al. Cost-effectiveness of drugs to treat relapsed/refractory Multiple Myeloma in the U.S. Journal of Managed Care & Specialty Pharmacy. 2017 (In Press).
Carlson JJ, Guzauskas G, Chapman R, et al. Cost-effectiveness of drugs to treat relapse/refractory multiple myeloma in the US. Poster presented at: International Society for Pharmacoeconomics and Outcomes Research; May 20-24, 2017; Boston, MA. PCN107
Multiple Sclerosis:
Multiple Sclerosis: Final Evidence Report
Brouwer E, Carlson JJ, Zimmermann M. Drug-specific discontinuation rates for available multiple sclerosis treatments. Poster presented at: International Society for Pharmacoeconomics and Outcomes Research; May 20-24, 2017; Boston, MA. PND14
Strand L, Zimmermann M, Carlson JJ, Hansen RN. Cost-utility of early versus delayed treatment with interferon beta-1b in clinically isolated syndrom (CIS) from a United States (US) payer perspective. Poster presented at: International Society for Pharmacoeconomics and Outcomes Research; May 20-24, 2017; Boston, MA. PND33
Zimmermann M, Brouwer E, Tice JA, et al. Cost-utility of disease modifying therapies for relapsing-remitting multiple sclerosis. Poster presented at: International Society for Pharmacoeconomics and Outcomes Research; May 20-24, 2017; Boston, MA. PND35
Osteoporosis:
Osteoporosis: Final Evidence Report
Psoriasis:
Psoriasis: Final Evidence Report and Meeting Summary
Hendrix N, Ollendorf DA, CHapman R, et al. Cost-effectiveness of targeted therapy for moderate-to-severe plaque psoriasis: an analysis based on an institute for clinical and economic review (ICER) report. Poster presented at: International Society for Pharmacoeconomics and Outcomes Research; May 20-24, 2017; Boston, MA. PSS17
Inherited Retinal Disease: